Cross-species genomics reveals oncogenic dependencies in ZFTA/C11orf95 fusion-positive supratentorial ependymomas

authors

  • Zheng Tuyu
  • Ghasemi David
  • Okonechnikov Konstantin
  • Korshunov Andrey
  • Sill Martin
  • Maass Kendra
  • Benites Goncalves da Silva Patricia
  • Ryzhova Marina
  • Gojo Johannes
  • Stichel Damian
  • Arabzade Amir
  • Kupp Robert
  • Benzel Julia
  • Taya Shinichiro
  • Adachi Toma
  • Shiraishi Ryo
  • Gerber Nicolas
  • Sturm Dominik
  • Ecker Jonas
  • Sievers Philipp
  • Selt Florian
  • Chapman Rebecca
  • Haberler Christine
  • Figarella‑branger Dominique
  • Reifenberger Guido
  • Fleischhack Gudrun
  • Rutkowski Stefan
  • Donson Andrew
  • Ramaswamy Vijay
  • Capper David
  • Ellison David
  • Herold-Mende Christel
  • Schuller Ulrich
  • Brandner Sebastian
  • Hernaiz Driever Pablo
  • Kros Johan
  • Snuderl Matija
  • Milde Till
  • Grundy Richard
  • Hoshino Mikio
  • Mack Stephen
  • Gilbertson Richard
  • Jones David T.W.
  • Kool Marcel
  • von Deimling Andreas
  • Pfister Stefan
  • Sahm Felix
  • Kawauchi Daisuke
  • Pajtler Kristian

abstract

Molecular groups of supratentorial ependymomas comprise tumors with ZFTA-RELA or YAP1-involving fusions and fusion-negative subependymoma. However, occasionally supratentorial ependymomas cannot be readily assigned to any of these groups due to lack of detection of a typical fusion and/or ambiguous DNA methylation-based classification. An unbiased approach with a cohort of unprecedented size revealed distinct methylation clusters composed of tumors with ependymal but also various other histological features containing alternative translocations that shared ZFTA as a partner gene. Somatic overexpression of ZFTA-associated fusion genes in the developing cerebral cortex is capable of inducing tumor formation in vivo, and cross-species comparative analyses identified GLI2 as a key downstream regulator of tumorigenesis in all tumors. Targeting GLI2 with arsenic trioxide caused extended survival of tumor-bearing animals, indicating a potential therapeutic vulnerability in ZFTA fusion-positive tumors.

more information